Skip to main content

Table 1 Patient characteristics

From: Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

  Clinical benefit (n = 4) No clinical benefit (n = 8)
Median age (range) 57 (38-78) 67 (52-77)
Sex 1 female 3 female
3 male 5 male
M-stage 0 M1A 2 M1A
2 M1B 0 M1B
2 M1C 6 M1C
Median baseline LDH 156 211 (183-438)
Karnofsky Performance 90 (90-100) 90 (90-100)